

# Optimal Timing of Coronary Intervention in Unstable Angina 2.

Gepubliceerd: 16-02-2013 Laatste bijgewerkt: 18-08-2022

To evaluate whether an urgent coronary intervention in NSTEMI-ACS patients, after initiation of state of the art medical therapy, is superior to an early strategy in terms of total myocardial damage measured as the AUC of CK-MB and short and long...

|                             |                          |
|-----------------------------|--------------------------|
| <b>Ethische beoordeling</b> | Positief advies          |
| <b>Status</b>               | Werving nog niet gestart |
| <b>Type aandoening</b>      | -                        |
| <b>Onderzoekstype</b>       | Interventie onderzoek    |

## Samenvatting

### ID

NL-OMON26173

### Bron

Nationaal Trial Register

### Verkorte titel

OPTIMA2

### Aandoening

NSTEMI-ACS; treatment strategy; Treatment Outcome; Time factors

Non ST hart infarct; Behandeling strategie; Behandeling uitkomsten; Tijdsfactor

## Ondersteuning

**Primaire sponsor:** Cardiology Research Department, Onze Lieve Vrouwe Gasthuis

**Overige ondersteuning:** fonds = verrichter = sponsor

## Onderzoeksproduct en/of interventie

## Uitkomstmaten

### Primaire uitkomstmaten

Size of MI during initial hospitalization as measured by the AUC of CK-MB.

## Toelichting onderzoek

### Achtergrond van het onderzoek

This study is a randomised and prospective open-label multicentre strategy trial in patients admitted with suspected high risk NSTEMI-ACS.

Approximately 350 patients admitted with NSTEMI-ACS and coronary anatomy suitable for PCI with stent-implantation will be randomized in a 1:1 fashion.

Informed consent will be obtained from all patients meeting the inclusion criteria before the initiation of any study-specific procedures. After informed consent, patients will be randomized using a computerized algorithm, to urgent PCI or early PCI. All patients will receive swift medical treatment which should be initiated at least 45 minutes before the PCI. The pharmacological therapy advised is pre-medication with a combination of strong, reliable and fast acting platelet inhibitors such as aspirin and a novel P2Y<sub>12</sub> inhibitor in combination with a safe anticoagulant. PCI, including adjunctive therapies, will be performed according to standard institutional practices. Stent implantation is mandatory in all patients. All patients will be followed from randomisation through to hospital discharge, with respect to any clinically significant events (death, MI, revascularisation, or major haemorrhage).

Three visits assessing MI (with ECG) and revascularisation procedures will be conducted at 30 days, 6 months and 12 months. The primary endpoint assessments are at the index hospitalization.

Countries of Recruitment: The Netherlands.

### Doel van het onderzoek

To evaluate whether an urgent coronary intervention in NSTEMI-ACS patients, after initiation of state of the art medical therapy, is superior to an early strategy in terms of total myocardial damage measured as the AUC of CK-MB and short and long-term clinical adverse events.

### Onderzoeksopzet

During hospitalization:

1. Baseline (T=0): hsTroponin, CK, CK-MB, HS-CRP, NT-proBNP, Hb, Ht, leucocytes, platelets, Na, K, Creatinine, BUN;
2. T= 6,12,24,30,36,42,48: hsTroponin, CK, CK-MB.

Discharge (after at least 48 hr):

At discharge: Troponin, CK, CK-MB, HS-CRP, NT-proBNP, echocardiography.

30 Days Follow Up:

At 30 days: Medical history, ECG, echocardiography.

6 and 12 months and 5 year Follow Up:

At 6 months: Medical history, ECG.

When recurrent ischemia is suspected another blood sample should be obtained to measure: hsTroponin, CK, CK-MB (T= Pain + 0) and at 6 hour intervals after the start of until the CK-MB value has normalized.

### **Onderzoeksproduct en/of interventie**

Diagnostic angiography: When to perform PCI:

After informed consent is obtained, the patient will be randomized to urgent or early angiography. During diagnostic angiography a culprit artery should be appointed if possible and be amenable to PCI with stenting. However, when multiple lesions are present the culprit should be among the lesions to be treated by PCI with stenting. In case of uncertainty, all lesions considered as likely “culprit” lesions should be treated with PCI and stent-implantation. The treatment strategy when multiple (non-culprit) lesions are present is at the discretion of the operator, whether it is complete or incomplete.

In the following cases PCI should not be performed:

Angiography not demonstrating significant coronary narrowing (no more than 50% by visual assessment in 3 orthogonal views of LCA, 2 of RCA). Patients to be treated by cardiac surgery in the opinion of the treating physician.

## **Contactpersonen**

### **Publiek**

Hogeweg 90-2  
F.J. Oosterwerff  
Amsterdam 1098 CH

The Netherlands  
+31 (0)6 19220860

## **Wetenschappelijk**

Hogeweg 90-2  
F.J. Oosterwerff  
Amsterdam 1098 CH  
The Netherlands  
+31 (0)6 19220860

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

1. Age > 21 years;
2. Typical chest pain for angina pectoris lasting at least 10 minutes, within the last 24 hours;
3. No contra-indication to PCI;
4. And at least one of the following criteria:
  - A. 1 mm of horizontal or downsloping ST depression;
  - B. Dynamic ST- or T- wave changes > 1 mm in two contiguous leads;
  - C. Elevated hs troponin (>1xULN);
  - D. Known coronary artery disease;
  - E. Two of following risk factors: DM, known hypertension, current smoking, family history for ischemic heart disease, hypercholesterolemia, peripheral artery disease, age over 60 years.

### **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

1. Acute ST myocardial infarction;
2. Refractory angina;

3. Severe heart failure;
4. Life-threatening ventricular arrhythmias;
5. Haemodynamic instability;
6. Contraindication for the use of a P2Y12 platelet receptor inhibitor;
7. Participation in another study;
8. Use of oral anticoagulants;
9. Patient is not capable of making a rational decision whether to participate, as is judged by investigators discretion.

## Onderzoeksopzet

### Opzet

|                  |                         |
|------------------|-------------------------|
| Type:            | Interventie onderzoek   |
| Onderzoeksmodel: | Parallel                |
| Toewijzing:      | Gerandomiseerd          |
| Blinding:        | Open / niet geblindeerd |
| Controle:        | Actieve controle groep  |

### Deelname

|                         |                          |
|-------------------------|--------------------------|
| Nederland               |                          |
| Status:                 | Werving nog niet gestart |
| (Verwachte) startdatum: | 01-03-2013               |
| Aantal proefpersonen:   | 350                      |
| Type:                   | Verwachte startdatum     |

## Ethische beoordeling

|                 |                  |
|-----------------|------------------|
| Positief advies |                  |
| Datum:          | 16-02-2013       |
| Soort:          | Eerste indiening |

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

| Register       | ID                                  |
|----------------|-------------------------------------|
| NTR-new        | NL3691                              |
| NTR-old        | NTR3861                             |
| Ander register | MEC : R12.032                       |
| ISRCTN         | ISRCTN wordt niet meer aangevraagd. |

## Resultaten

### Samenvatting resultaten

N/A